Herpes Zoster News and Research

RSS
Herpes Zoster, also called shingles, is a painful skin rash caused by the varicella-zoster virus, the same virus that causes chickenpox. After a person recovers from chickenpox, the virus remains inactive in the body. Usually the virus does not cause any further problems; however, the virus may re-emerge years later, causing shingles.
Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Pluristem's PLacental eXpanded cell therapy effective against neuropathic and inflammatory nerve pain

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Summer Academy Meeting highlights benefits of HPV, Herpes Zoster vaccines

Merck reports strong bottom-line performance in second quarter

Merck reports strong bottom-line performance in second quarter

Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles

Independent DSMB recommends Inhibitex to complete FV-100 Phase II clinical trial for shingles

Aestus Therapeutics announces license agreement with Astellas Pharma

Aestus Therapeutics announces license agreement with Astellas Pharma

Combination MMRV vaccine associated with increased risk of febrile seizures

Combination MMRV vaccine associated with increased risk of febrile seizures

FDA approves Roxane Laboratories' Valacyclovir Hydrochloride Tablets ANDA

FDA approves Roxane Laboratories' Valacyclovir Hydrochloride Tablets ANDA

NIH awards Aestus $2M SBIR grant for clinical trials of treatment for chronic neuropathic pain

NIH awards Aestus $2M SBIR grant for clinical trials of treatment for chronic neuropathic pain

FDA accepts Depomed's DM-1796 NDA for pain after shingles

FDA accepts Depomed's DM-1796 NDA for pain after shingles

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

FDA approves Watson Pharmaceuticals' generic version of VALTREX tablets

FDA approves Watson Pharmaceuticals' generic version of VALTREX tablets

Data from RGN-259 study published in Archives of Ophthalmology

Data from RGN-259 study published in Archives of Ophthalmology

Inhibitex reports net loss of $4.8M for first-quarter 2010

Inhibitex reports net loss of $4.8M for first-quarter 2010

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Advances in genetic research could help develop personalized pain medications

Advances in genetic research could help develop personalized pain medications

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Study evaluates cost benefits of new interventions for treating, preventing PDN and PHN

Study evaluates cost benefits of new interventions for treating, preventing PDN and PHN

New data on Cladribine Tablets presented at AAN annual meeting

New data on Cladribine Tablets presented at AAN annual meeting

Depomed licensee submits DM-1796 NDA for management of PHN

Depomed licensee submits DM-1796 NDA for management of PHN

Inhibitex announces net loss of $4.7M for fourth-quarter 2009

Inhibitex announces net loss of $4.7M for fourth-quarter 2009